Matarin Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Matarin Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-75,473	Closed	-$3.54M	–	212
2015 Q1	$3.54M	Buy	75,473 +22,541	+43%	+$897K	1.07%	14
2014 Q4	$1.68M	Hold	52,932	–	–	0.74%	62
2014 Q3	$1.26M	Sell	52,932 -25,360	-32%	-$650K	0.58%	79
2014 Q2	$2.35M	Buy	78,292 +14,375	+22%	+$388K	1.05%	13
2014 Q1	$1.69M	Sell	63,917 -8,876	-12%	-$222K	1%	29
2013 Q4	$1.83M	Buy	72,793 +29,819	+69%	+$665K	1.13%	36
2013 Q3	$880K	Buy	42,974 +6,503	+18%	+$134K	0.74%	59
2013 Q2	$727K	Buy	+36,471	New	+$647K	0.73%	50

Other funds holding IPXL

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Hound Partners New York $863M AUM 11.22% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Matarin Capital Management's IPXL Position: Q2 2015 in Review

Matarin Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2015, closing a stake of 75,473 shares — an estimated $3.54M sold.

Matarin Capital Management first reported a position in IPXL in Q2 2013 and held it in 8 quarters. The position peaked at $3.54M in Q1 2015. 197 funds tracked by Wall St. Rank hold IPXL as of Q2 2015.

Matarin Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2015 after selling out during the quarter.
Matarin Capital Management sold 75,473 Impax Laboratories, Inc. shares in Q2 2015, an estimated $3.54M.
Matarin Capital Management first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 8 quarters.
Matarin Capital Management's Impax Laboratories, Inc. position peaked at $3.54M in Q1 2015.
197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2015.

Based on Matarin Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.